Xtane is used in the treatment of breast cancer in women who have gone through menopause.
Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 2005. Exemestane is also indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.[
Brand Name "Xtane (Exemestane tablets 25 mg)" medication can be imported and made available on "Named Patient Program (NPP)" treatment in Philippines, Vietnam, Ireland and India. Please contact at +91 9910645395 (Mr. Rakesh) or make an enquiry at info@cancermedicinesnetwork to find the cost price to buy "Xtane (Exemestane tablets 25 mg)" online and have it delivered where you live. We take guarantee of quality and delivery as per the buyer’s requirements.
Patient, Physcian, distributor/supplier can buy and import Brand Name "Xtane (Exemestane tablets 25 mg)" from Verve Biosciences, if the drug has not been approved or is not available in your country. Make an enquiry and we will help you calculate the total price to buy "Xtane (Exemestane tablets 25 mg)" online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Verve Biosciences facilitates import of anti-cancer medicines Xtane (Exemestane tablets 25 mg), Make an enquiry to find the total cost of Xtane (Exemestane tablets 25 mg) in UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.